Vascular Biogenics Ltd (VBLT) Position Cut by Raymond James & Associates

Raymond James & Associates cut its stake in Vascular Biogenics Ltd (NASDAQ:VBLT) by 37.6% during the 4th quarter, HoldingsChannel reports. The fund owned 54,400 shares of the biopharmaceutical company’s stock after selling 32,742 shares during the period. Raymond James & Associates’ holdings in Vascular Biogenics were worth $53,000 as of its most recent SEC filing.

Separately, First Republic Investment Management Inc. acquired a new stake in shares of Vascular Biogenics during the third quarter worth $438,000. 13.96% of the stock is owned by hedge funds and other institutional investors.

A number of analysts have weighed in on the stock. Zacks Investment Research raised shares of Vascular Biogenics from a “sell” rating to a “hold” rating in a report on Saturday, March 30th. Chardan Capital reissued a “neutral” rating on shares of Vascular Biogenics in a report on Wednesday, March 13th. HC Wainwright reissued a “buy” rating and set a $3.00 target price on shares of Vascular Biogenics in a report on Tuesday, January 15th. Finally, ValuEngine raised shares of Vascular Biogenics from a “sell” rating to a “hold” rating in a report on Thursday, January 3rd.

Shares of NASDAQ:VBLT opened at $1.41 on Friday. The firm has a market cap of $50.23 million, a price-to-earnings ratio of -2.27 and a beta of -0.16. Vascular Biogenics Ltd has a 1-year low of $0.60 and a 1-year high of $3.10. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.83 and a current ratio of 10.83.

Vascular Biogenics (NASDAQ:VBLT) last issued its earnings results on Thursday, March 28th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.17) by $0.07. The company had revenue of $0.14 million for the quarter, compared to analysts’ expectations of $0.30 million. Vascular Biogenics had a negative net margin of 3,497.09% and a negative return on equity of 37.01%. As a group, equities research analysts anticipate that Vascular Biogenics Ltd will post -0.61 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Vascular Biogenics Ltd (VBLT) Position Cut by Raymond James & Associates” was reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this piece on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.baseballdailydigest.com/news/2019/04/21/vascular-biogenics-ltd-vblt-position-cut-by-raymond-james-associates.html.

Vascular Biogenics Company Profile

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels.

Featured Story: How to interpret a stock’s beta number

Want to see what other hedge funds are holding VBLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vascular Biogenics Ltd (NASDAQ:VBLT).

Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.